Definition And Principles

Enzyme replacement therapy (ERT) involves the intravenous or intrathecal administration of recombinant or purified human lysosomal enzymes.
It aims to replace deficient enzymes in lysosomal storage disorders (LSDs) and other metabolic conditions, thereby preventing or reversing toxic substrate accumulation.
ERT provides a continuous exogenous enzyme supply but is not curative, necessitating lifelong therapy.

Mechanism Of Action And Pathophysiology

Recombinant therapeutic enzymes are modified with mannose-6-phosphate (M6P) residues.
These residues facilitate targeted receptor-mediated endocytosis via M6P receptors located on the host cell surface.
Following cellular internalization, enzymes are trafficked directly to the lysosomes.
Within the lysosome, the exogenous enzyme degrades accumulated substrates, such as glucocerebroside in Gaucher disease, glycosaminoglycans (GAGs) in mucopolysaccharidoses (MPS), or glycogen in Pompe disease.
Efficacy produces a dose-dependent reduction in substrate burden, heavily relying on early initiation before irreversible tissue damage occurs.
Conventional intravenously administered ERT does not cross the blood-brain barrier (BBB), offering no clinical benefit for central nervous system (CNS) manifestations in neuronopathic disease variants.

Disease Category	Specific Condition	Deficient Enzyme	Approved ERT Agents	Clinical Benefit
Sphingolipidoses	Gaucher Disease (Type 1, 3)	Glucocerebrosidase	Imiglucerase, Velaglucerase alfa, Taliglucerase alfa	Reduces hepatosplenomegaly, improves anemia and thrombocytopenia.
	Fabry Disease	Alpha-galactosidase A	Agalsidase alfa, Agalsidase beta, Pegunigalsidase alfa	Prevents renal and cardiac disease progression.
	ASMD (Niemann-Pick B)	Acid sphingomyelinase	Olipudase alfa	Reduces hepatosplenomegaly, improves lung function.
Glycogen Storage	Pompe Disease (IOPD/LOPD)	Acid alpha-glucosidase (GAA)	Alglucosidase alfa, Avalglucosidase alfa, Cipaglucosidase alfa	Improves cardiomyopathy, ventilation-free survival, and motor function.
Mucopolysaccharidoses	MPS I (Hurler/Scheie)	Alpha-L-iduronidase (IDUA)	Laronidase	Reduces GAGs, improves joint mobility and respiratory function.
	MPS II (Hunter)	Iduronate-2-sulfatase (IDS)	Idursulfase	Reduces GAGs, improves visceral symptoms.
	MPS IVA (Morquio A)	Galactose-6-sulfatase (GALNS)	Elosulfase alfa	Improves respiratory function and physical endurance.
	MPS VI (Maroteaux-Lamy)	Arylsulfatase B (ARSB)	Galsulfase	Skeletal and visceral improvement.
	MPS VII (Sly)	Beta-glucuronidase (GUSB)	Vestronidase alfa	Reduces GAGs, improves mobility.
Other Disorders	Lysosomal Acid Lipase Deficiency	Lysosomal acid lipase	Sebelipase alfa	Prevents liver failure and adrenal calcification.
	Alpha-Mannosidosis	Alpha-mannosidase	Velmanase alfa	Substrate clearance.

Administered via intravenous infusion every one to two weeks, utilizing disease-specific weight-based dosing protocols.
Premedication with antihistamines, antipyretics, or corticosteroids is required to prevent infusion-related reactions (IRRs).
Home therapy administration is feasible following clinical stabilization, often utilizing a port-a-cath in young pediatric patients.

Baseline pre-treatment assessments require echocardiography, pulmonary function tests, MRI (liver, spleen, bone), and six-minute walk tests.
Routine clinical monitoring occurs every three to six months to rigorously assess clinical improvement and biochemical markers.
Target monitoring biomarkers include chitotriosidase and Lyso-Gb1 for Gaucher disease, and urinary GAG excretion for MPS.
Cross-reactive immunological material (CRIM) status must be evaluated in Pompe disease; CRIM-negative patients mandatorily require immune tolerance induction (ITI) to prevent neutralizing antibodies,.
Anti-drug antibodies (ADA) are monitored sequentially, as elevated titers can significantly reduce therapeutic enzyme efficacy,.

Neurological Limitations: Standard ERT cannot penetrate the BBB, rendering it ineffective for neuronopathic conditions like Gaucher type 2/3 and MPS neuronopathic forms. Intrathecal trials are currently ongoing to bypass this limitation,.
Immunogenicity: The development of neutralizing ADAs reduces efficacy, necessitating ITI protocols utilizing agents like rituximab, methotrexate, or IVIG.
Incomplete Efficacy: Residual disease progression often persists in poorly vascularized target tissues, including the skeleton, cornea, and heart valves.
Adverse Events: Infusion-related hypersensitivity and anaphylactic reactions occur in 10-50% of patients.
Financial Toxicity: Extreme treatment costs pose massive barriers to equitable healthcare access, demanding lifelong financial support or government subsidies.

Prognosis improves dramatically with early initiation; infantile-onset Pompe disease survival increases from less than one year to over two decades with combined ERT and ITI.
Visceral manifestations exhibit high reversibility if ERT is initiated within the first six months of life.
Next-generation therapeutic pipelines focus on BBB-crossing fusion proteins, substrate reduction therapy (SRT) combinations, and acting as a bridge to definitive gene therapy.